{"analyses":[{"ciPctValue":"95","groupDescription":"Interim futility analysis of the alternative hypothesis for disease-free survival. The design specified a hazard ratio of (observation: GO) of 1.5.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalComment":"The interim analysis only reported a p-value for testing whether the hazard ratio was not equal to 1.5.","statisticalMethod":"Regression, Cox","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27","upperLimit":"51","value":"39"},{"groupId":"OG001","lowerLimit":"38","upperLimit":"62","value":"50"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"84"}],"units":"Participants"}],"description":"Measured from data of randomization to post-consolidation therapy until relapse from complete response or death from any cause, with observations censored at the date of last contact for patients last known to be alive without report of relapse.","dispersionType":"95% Confidence Interval","groups":[{"description":"For patients who remain in CR without relapse, patients may receive up to 3 doses of G.O. 28 days apart.","id":"OG000","title":"Post-consolidation GO"},{"description":"Patients did not receive any post-consolidation therapy","id":"OG001","title":"Post-consolidation Observation"}],"paramType":"NUMBER","populationDescription":"Eligible patients who completed induction and consolidation therapy","reportingStatus":"POSTED","timeFrame":"After completing any treatment, every 6 months for 2 years, than annually for years 3-5","title":"2-year Disease-free Survival (DFS)","type":"PRIMARY","unitOfMeasure":"Percentage of population"}